Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)
Latest Information Update: 23 Jun 2020
At a glance
- Drugs Dihydroartemisinin/piperaquine (Primary) ; Interferon alpha; Umifenovir
- Indications COVID 2019 infections; Pneumonia
- Focus Therapeutic Use
Most Recent Events
- 23 Jun 2020 New trial record